Amyloid-beta peptide enhances tumor necrosis factor-alpha-induced iNOS through neutral sphingomyelinase/ceramide pathway in oligodendrocytes

J Neurochem. 2005 Aug;94(3):703-12. doi: 10.1111/j.1471-4159.2005.03217.x.

Abstract

Although accumulating evidence demonstrates that white matter degeneration contributes to pathology in Alzheimer's disease (AD), the underlying mechanisms are unknown. In order to study the roles of the amyloid-beta peptide in inducing oxidative stress damage in white matter of AD, we investigated the effects of amyloid-beta peptide 25-35 (Abeta) on proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha)-induced inducible nitric oxide synthase (iNOS) in cultured oligodendrocytes (OLGs). Although Abeta 25-35 by itself had little effect on iNOS mRNA, protein, and nitrite production, it enhanced TNF-alpha-induced iNOS expression and nitrite generation in OLGs. Abeta, TNF-alpha, or the combination of both, increased neutral sphingomyelinase (nSMase) activity, but not acidic sphingomyelinase (aSMase) activity, leading to ceramide accumulation. Cell permeable C2-ceramide enhanced TNF-alpha-induced iNOS expression and nitrite generation. Moreover, the specific nSMase inhibitor, 3-O-methyl-sphingomyelin (3-OMS), inhibited iNOS expression and nitrite production induced by TNF-alpha or by the combination of TNF-alpha and Abeta. Overexpression of a truncated mutant of nSMase with a dominant negative function inhibited iNOS mRNA production. 3-OMS also inhibited nuclear factor kappaB (NF-kappaB) binding activity induced by TNF-alpha or by the combination of TNF-alpha and Abeta. These results suggest that neutral sphingomyelinase/ceramide pathway is required but may not be sufficient for iNOS expression induced by TNF-alpha and the combination of TNF-alpha and Abeta.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amyloid beta-Peptides / pharmacology*
  • Analysis of Variance
  • Animals
  • Animals, Newborn
  • Blotting, Western / methods
  • Cells, Cultured
  • Ceramides / metabolism*
  • Ceramides / pharmacology
  • Cerebral Cortex / cytology
  • Chromatography, Thin Layer / methods
  • Drug Interactions
  • Electrophoretic Mobility Shift Assay / methods
  • Enzyme Inhibitors / pharmacology
  • Green Fluorescent Proteins / metabolism
  • Infections
  • Mutagenesis / physiology
  • NF-kappa B / metabolism
  • Neurons / drug effects
  • Neurons / enzymology
  • Nitric Oxide Synthase / genetics
  • Nitric Oxide Synthase / metabolism*
  • Nitric Oxide Synthase Type II
  • Nitrites / metabolism
  • Oligodendroglia / drug effects*
  • Oligodendroglia / enzymology
  • Peptide Fragments / pharmacology
  • RNA, Messenger / biosynthesis
  • Radioligand Assay / methods
  • Rats
  • Reverse Transcriptase Polymerase Chain Reaction / methods
  • Sphingomyelin Phosphodiesterase / metabolism*
  • Sphingomyelin Phosphodiesterase / pharmacology
  • Stem Cells / physiology
  • Tetrazolium Salts
  • Thiazoles
  • Transfection / methods
  • Tumor Necrosis Factor-alpha / pharmacology*

Substances

  • Amyloid beta-Peptides
  • Ceramides
  • Enzyme Inhibitors
  • NF-kappa B
  • Nitrites
  • Peptide Fragments
  • RNA, Messenger
  • Tetrazolium Salts
  • Thiazoles
  • Tumor Necrosis Factor-alpha
  • Green Fluorescent Proteins
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Nos2 protein, rat
  • Sphingomyelin Phosphodiesterase
  • thiazolyl blue